ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.162,53
0,00%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06979
-0,11%
Bitcoin
61.536,41
-0,44%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) News

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202414h01Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KPTIKaryopharm Therapeutics Inc
10/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KPTIKaryopharm Therapeutics Inc
06/06/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/06/202422h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/06/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
01/06/202419h45PR Newswire (US)Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesNASDAQ:KPTIKaryopharm Therapeutics Inc
31/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202423h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202423h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202422h44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
29/05/202422h05PR Newswire (US)Karyopharm to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
23/05/202422h30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422h05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202422h30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202422h01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
01/04/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202422h05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202401h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202401h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202401h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Kürzlich von Ihnen besucht

BIT
P21YB7
NLBNPIT21YB7 20240621 9.5
AMEX
AST
Asterias Biotherapeutics, Inc.
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten